Literature DB >> 10189897

Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.

M Ando1, Y Ando, S Sugiura, H Minami, H Saka, S Sakai, K Shimokata, Y Hasegawa.   

Abstract

Prognostic factors which can forecast short-term survival in patients with stage IV non-small cell lung cancer have not been well evaluated. Characteristics of such factors may be different from those for overall survival, and would be an important eligibility criterion for clinical trials of chemotherapy. We retrospectively analyzed the data of 158 patients with stage IV non-small cell lung cancer whose performance status was 0, 1 or 2. Univariate and multivariate logistic regression models revealed demographic variables which significantly correlated with the survival at 8 or 12 weeks. The univariate model showed the following significant variables: T factor, N factor, number of organs with metastases, grade of performance status, weight loss within 6 months, evidence of metastasis either at bone or lymph node, and lactate dehydrogenase level. The subsequent multivariate model demonstrated that both grade of performance status under 2 and number of metastasized organs less than 3 are important factors for 8- or 12-week survival. The survival rate in patients meeting the two criteria (grade of performance status under 2 and number of metastasized organs less than 3) and in those meeting only one of them was 93% versus 80% at 8 weeks (P = 0.030) and 88% versus 62% at 12 weeks (P < 0.001), respectively. Grade of performance status and number of organs with metastases appear to be important prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.

Entities:  

Mesh:

Year:  1999        PMID: 10189897      PMCID: PMC5926048          DOI: 10.1111/j.1349-7006.1999.tb00740.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  11 in total

Review 1.  Chemotherapy of lung cancer.

Authors:  D C Ihde
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

2.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Authors:  J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

3.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

4.  Prognostic uncertainty in terminal care: can the Karnofsky index help?

Authors:  C Evans; M McCarthy
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

Review 5.  Treatment of advanced non-small cell lung cancer.

Authors:  F A Shepherd
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

6.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

Authors:  J C Ruckdeschel; D M Finkelstein; D S Ettinger; R H Creech; B A Mason; R A Joss; S Vogl
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

7.  Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.

Authors:  D M Finkelstein; D S Ettinger; J C Ruckdeschel
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

8.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

Authors:  M Paesmans; J P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O Van Cutsem; R Sergysels; P Mommen
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

9.  A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.

Authors:  T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; T Miya; H Okamoto; K Iemura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients.

Authors:  J B Sørensen; J H Badsberg; J Olsen
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

View more
  4 in total

1.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

2.  Predictors of survival in patients with bone metastasis of lung cancer.

Authors:  Hideshi Sugiura; Kenji Yamada; Takahiko Sugiura; Toyoaki Hida; Tetsuya Mitsudomi
Journal:  Clin Orthop Relat Res       Date:  2008-01-03       Impact factor: 4.176

3.  Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6.

Authors:  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-07

Review 4.  Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).

Authors:  Ralph Zinner; Carla Visseren-Grul; David R Spigel; Coleman Obasaju
Journal:  Int J Oncol       Date:  2015-10-29       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.